121 related articles for article (PubMed ID: 32156890)
1. [Skin Ulcer Caused by Bevacizumab-A Case Report].
Mori Y; Ishikawa A; Urano N; Higuchi I; Gofuku J; Hasuike Y
Gan To Kagaku Ryoho; 2019 Dec; 46(13):2237-2239. PubMed ID: 32156890
[TBL] [Abstract][Full Text] [Related]
2. [A Case of Cecal Cancer with Liver and Lung Metastases That Maintained Long Stable Disease by TFTD and Bevacizumab Chemotherapy].
Takeuchi M
Gan To Kagaku Ryoho; 2018 Nov; 45(11):1657-1660. PubMed ID: 30449858
[TBL] [Abstract][Full Text] [Related]
3. Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study.
Nagasaka T; Mishima H; Sawaki A; Shimokawa M; Inukai M; Shinozaki K; Tanioka H; Nasu J; Nishina T; Hazama S; Okajima M; Yamaguchi Y
BMJ Open; 2016 Jun; 6(6):e011454. PubMed ID: 27256093
[TBL] [Abstract][Full Text] [Related]
4. [Complete resection of liver metastases of colorectal cancer after high efficacy bevacizumab, S-1, and CPT -11 combination chemotherapy].
Imai H; Sawada K; Sato A; Nishi K; Sasaki T; Takahashi T; Ohori H
Gan To Kagaku Ryoho; 2015 Jan; 42(1):101-4. PubMed ID: 25596689
[TBL] [Abstract][Full Text] [Related]
5. [A Retrospective Case Study of Combination Chemotherapy with Bevacizumab for Recurrent Ovarian Cancer].
Hori K; Tsuruta T; Odani C; Ono H; Ohkubo R; Shimoji K; Murakami J; Nakagawa M; Tashima L; Ito K
Gan To Kagaku Ryoho; 2016 Oct; 43(10):1197-1200. PubMed ID: 27760937
[TBL] [Abstract][Full Text] [Related]
6. Large Skin Ulcer Due to a Subcutaneous Orthopaedic Implant After Bevacizumab Therapy: A Case Report.
Suehara Y; Osawa H; Kubota D; Kato S; Akaike K; Tanabe Y; Saito T; Kaneko K
JBJS Case Connect; 2016; 6(3):e70. PubMed ID: 29252647
[TBL] [Abstract][Full Text] [Related]
7. [Safety and Efficacy of TAS-102 with Bevacizumab for the Treatment of Unresectable Metastatic Colorectal Cancer - A Case Report].
Arakawa S; Horiguchi A; Tomishige H; Kawabe N; Nagata H; Ishihara S; Ito M; Asano Y; Ito R; Isetani M; Shimizu K; Kamio K; Kawai T; Yasuoka H; Imaeda Y
Gan To Kagaku Ryoho; 2018 Apr; 45(4):649-651. PubMed ID: 29650823
[TBL] [Abstract][Full Text] [Related]
8. [Cetuximab-associated skin ulceration in patient with metastatic colorectal cancer: a case report].
Tsuboi K; Kawase Y; Okochi O; Hattori M; Takami Y; Takeda S; Mizuno A; Sato Y; Uno Y; Hayashi T; Sasada Y; Takamura S; Kozaki K
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1549-52. PubMed ID: 21918361
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of Negative Pressure Wound Therapy for Post-Operative Wound Dehiscence after Resection of a Metastatic AbdominalWal lTumor from Cecal Cancer during Chemotherapy with Bevacizumab].
Maeda H; Yoshimatsu K; Kono T; Ito Y; Imaizumi R; Koike T; Ida A; Yamada Y; Okayama S; Yokomizo H; Shiozawa S
Gan To Kagaku Ryoho; 2019 Oct; 46(10):1647-1649. PubMed ID: 31631163
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of re-induction therapy with bevacizumab and paclitaxel for metastatic breast cancer.
Yoshinami T; Yagi T; Okuno J; Kittaka N; Ishitobi M; Sugimoto N; Nakayama T; Tamaki Y; Imamura F
Breast Cancer; 2017 Jan; 24(1):147-151. PubMed ID: 27010394
[TBL] [Abstract][Full Text] [Related]
11. [A case of cecum colon cancer with lymph node metastasis successfully treated with XELOX plus bevacizumab].
Ito S; Ichikawa R; Kure K; Honjo K; Aoki J; Okazawa Y; Mizukoshi K; Ro H; Kawai M; Takehara K; Okubo H; Ishiyama S; Sugimoto K; Komiyama H; Takahashi M; Yaginuma Y; Kojima Y; Goto M; Tomiki Y; Sakamoto K
Gan To Kagaku Ryoho; 2014 Nov; 41(11):1425-8. PubMed ID: 25434448
[TBL] [Abstract][Full Text] [Related]
12. [XELIRI plus Bmab Therapy as a Secondary Treatment for Recurrent Colorectal Cancer with Long-Term Survival].
Yukimoto R; Fukunaga M; Konishi K; Matsuno Y; Nakai S; Takiguchi N; Honda S; Saito A; Takeoka T; Okada K; Ota H; Yokoyama S; Kobayashi K
Gan To Kagaku Ryoho; 2019 Feb; 46(2):369-371. PubMed ID: 30914563
[TBL] [Abstract][Full Text] [Related]
13. [Two Cases of Rectal Cancer Resected Curatively after Chemotherapy with CapeOX plus Bmab].
Chiku T; Sano W; Hashiba T; Togawa Y
Gan To Kagaku Ryoho; 2015 Nov; 42(12):1647-9. PubMed ID: 26805125
[TBL] [Abstract][Full Text] [Related]
14. [A case report of stage IV cecal cancer exhibiting a complete response to multidisciplinary therapy].
Matsuyama T; Ishikawa T; Masuda T; Okazaki S; Ishiguro M; Kobayashi H; Iida S; Uetake H; Sugihara K
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2246-8. PubMed ID: 23268038
[TBL] [Abstract][Full Text] [Related]
15. [A Case of Aortoesophageal Fistula Rupture Due to Descending Thoracic Aortic Dissection with Recurrent Colon Cancer during Chemotherapy Containing Bevacizumab].
Koda T; Koike J; Masuhara H; Kurihara A; Shiokawa H; Ushigome M; Kaneko T; Suzuki T; Sawaguchi Y; Katayanagi T; Fujii T; Watanabe Y; Funahashi K; Shimada H; Kaneko H
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1815-1817. PubMed ID: 28133141
[TBL] [Abstract][Full Text] [Related]
16. Multiple large skin ulcers developed in a colon cancer patient treated with bevacizumab.
Wei H; Dong X; Hu X
Asian J Surg; 2023 Dec; 46(12):6107-6108. PubMed ID: 37777414
[No Abstract] [Full Text] [Related]
17. A case of multiple hepatocellular carcinoma experiencing complete responses to sorafenib and atezolizumab-bevacizumab and developing severe, refractory venous congestive cutaneous ulcers on either regimen.
Hayashi Y; Kaneko R; Ogino H; Uekusa T; Kitajima M; Ikehara T; Nagai H; Matsuda T
Clin J Gastroenterol; 2023 Apr; 16(2):229-236. PubMed ID: 36624210
[TBL] [Abstract][Full Text] [Related]
18. [A case report-bleeding from the ulcer of wound for mastectomy after postoperative chemotherapy with bevacizumab for Sigmoid colon cancer].
Tsumuraya M; Fujita M; Muroi H; Sugawara A; Tsubaki M; Kato H
Gan To Kagaku Ryoho; 2011 Nov; 38(11):1869-71. PubMed ID: 22083200
[TBL] [Abstract][Full Text] [Related]
19. [A Case of Metastatic Colorectal Cancer with Brain Metastasis Treated with Combined TFTD and Bevacizumab Therapy].
Takano J; Matsuhashi N; Takahashi T; Tanahashi T; Matsui S; Imai H; Tanaka Y; Yamaguchi K; Yoshida K
Gan To Kagaku Ryoho; 2018 Feb; 45(2):318-320. PubMed ID: 29483433
[TBL] [Abstract][Full Text] [Related]
20. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
Imai K; Emi Y; Iyama KI; Beppu T; Ogata Y; Kakeji Y; Samura H; Oki E; Akagi Y; Maehara Y; Baba H;
Eur J Surg Oncol; 2014 May; 40(5):559-566. PubMed ID: 24388740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
